title: [Fixed-dose combination fluticasone propionate/formoterol for the treatment of asthma: a review of its pharmacology, efficacy and tolerability].
abstract: The fixed-dose combination fluticasone propionate/formoterol (FPF) is a novel combination of a widely known and used inhaled glucocorticoid (IGC) and a long-acting β2-adrenergic agonist (LABA), available for the first time in a single device. This fixed-dose combination of FPF has a demonstrated efficacy and safety profile in clinical trials compared with its individual components and other fixed-dose combinations of IGC/LABA and is indicated for the treatment of persistent asthma in adults and adolescents. FPF is available in a wide range of doses that can adequately cover the therapeutic steps recommended by treatment guidelines, constituting a fixed-dose combination of GCI/LABA that is effective, rapid, well tolerated and with a reasonable acquisition cost. Various assessment agencies of the Spanish Autonomous Communities consider this combination to be an appropriate alternative therapy for asthma in the primary care setting.
authors.affiliation: Medicina de Familia, Neumólogo, Centro de Salud Lucena I, Córdoba, España Coordinador Nacional del Grupo de Trabajo de Respiratorio de SEMERGEN. Electronic address: quintanojimenez@gmail.com.
authors.forename: J A
authors.initials: JA
authors.lastname: Quintano Jiménez
authors.affiliation: Medicina de Familia, Centro de Salud Ciudad Jardín, Málaga, España.
authors.forename: L
authors.initials: L
authors.lastname: Ginel Mendoza
authors.affiliation: Servicio de Neumología, Hospital Universitario Reina Sofía, Córdoba, España.
authors.forename: L M
authors.initials: LM
authors.lastname: Entrenas Costa
authors.affiliation: Medicina de Familia, Centro de Salud Cañaveral, Cáceres, España.
authors.forename: J
authors.initials: J
authors.lastname: Polo García
mesh_terms: D000293:Adolescent; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004983:Ethanolamines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068298:Fluticasone; D000068759:Formoterol Fumarate; D005938:Glucocorticoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic; D011320:Primary Health Care; D013030:Spain
chemical_list: D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D004338:Drug Combinations; D004983:Ethanolamines; D005938:Glucocorticoids; C586520:fluticasone-formoterol; D000068298:Fluticasone; D000068759:Formoterol Fumarate
keywords: Agonista β2-adrenérgico de acción larga; Asma; Asthma; Bronchodilator; Broncodilatador; Fluticasona propionato; Fluticasone propionate; Formoterol fumarate; Formoterol fumarato; Glucocorticoides inhalados; Inhaled corticosteroid; Long-acting β2-agonist